CORONA Remedies Posts 30.1% Profit After Tax Growth in Q1FY27; Highlights Strategic Acquisitions and Facility Expansion

CORONA Remedies Posts 30.1% Profit After Tax Growth in Q1FY27; Highlights Strategic Acquisitions and Facility Expansion​

CORONA Remedies Limited reported robust performance for the quarter ended June 30, 2026 (Q1FY27). The company achieved a Profit After Tax of ₹60.1 Crores, marking a 30.1% increase compared to Q1FY26, while Revenue from Operations reached ₹422.4 Crores, up 21.9%.

The company continues to demonstrate strong market positioning, with reports indicating that CORONA is among the fastest-growing companies in the top 30 Pharma firms for both MAT June-26 and Q1 ended June-26, according to Pharmatrac. The company successfully renewed its EU-GMP certification for the Oral Solid Dosage facility at its Bhayla plant in May 2026 and inaugurated a Hormone Facility with EU-GMP certification at the same location in June 2026.

Q1FY27 Financial Performance Overview​

The performance metrics show significant improvements across profitability indicators:

Strategic Milestones and Portfolio Expansion​

CORONA Remedies has steadily expanded its manufacturing ecosystem and bolstered its brand portfolio through strategic moves. Key highlights include:

• Manufacturing Excellence: The company operates a State of the Art Manufacturing Ecosystem, which incorporates multi dosage forms such as tablets, soft gel capsules, ointments, and gels.
• Geographic & Certification Expansion: The company received EAEU GMP accreditation for its Ahmedabad facility in 2022, followed by EU GMP accreditation for this plant in 2026. The Bhayla facility (Gujarat) holds EU-GMP certification.
• Acquisitions and Collaborations: CORONA has significantly scaled up acquired brands, including Dilo (from GSK), Stelbid and Vitneurin (from Glaxo Group Limited), Thyrocab Obimet (from Abbott India Limited), Myoril (from Sanofi Healthcare India Private Limited), 7 distinct brands from Bayer Zydus Pharma Ltd, and Wokadine (from Dr. Reddy's Laboratories Ltd).
• Backward Integration: The company made an investment in La Chandra Pharmalabs Private Limited to facilitate backward integration into Hormone API manufacturing.
• Therapeutic Focus: Chronic and sub-chronic therapies contribute approximately 73.4% of the business for Q1FY27, reflecting a strategic shift towards this segment.

Market Positioning and Growth Trajectory​

The company’s competitive edge is highlighted by its demonstrated success in execution excellence and market penetration. The focus remains on achieving sustainable growth through brand building and portfolio diversification.

Key operational metrics provided in the presentation include:

• Brand Portfolio: The company manages 79 brands across 33 engines, with the top 5 brands accounting for approximately 35% of revenue.
• Market Ranking: CORONA improved its ranking to 26th in MAT June-26 from 27th in MAT March 2026 within IPM (Indian Pharmaceutical Market). In specialized segments, it ranked #5 in Women's Healthcare and #5 in Pain Management.

Historical Financial Context​

Reviewing the historical trend, the company showed consistent top-line growth:


The company maintains a significant non-current asset base as of March 26, with Non Current Assets totaling ₹856.8 Crores and Total Assets standing at ₹1,205.1 Crores.

CORONA Stock Price Movement​

On Friday, shares of CORONA Remedies Limited edged higher, closing at ₹2098.8 after gaining 0.43%.The stock finished its session in robust territory, near its 52-week high and having seen 18,140 shares traded during the previous day's activity.